{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:34:59Z","timestamp":1793370899356,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA281701, P50CA127001, U24CA274212"],"award-info":[{"award-number":["P50CA281701, P50CA127001, U24CA274212"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The US Food and Drug Administration (FDA) launched Project Optimus and issued guidance to reform dose-finding and selection trials, shifting the paradigm from identifying the maximum tolerated dose (MTD) to determining the optimal biological dose (OBD), which optimizes the risk and benefit of treatments. The FDA\u2019s guidance emphasizes the importance of collecting sufficient toxicity and efficacy data across multiple doses and considering late-onset cumulative toxicity that often results in tolerability issues. To address these challenges, we propose the BE-BOIN (Backfill time-to-Event Bayesian Optimal INterval) design, which allows backfilling patients into safe and effective doses during dose escalation and accommodates late-onset toxicities. BE-BOIN enables the collection of additional safety and efficacy data to enhance the accuracy and reliability of OBD selection and supports real-time dose decisions for new patients. Our simulation studies show that BE-BOIN accurately identifies the MTD and OBD while significantly reducing trial duration.<\/jats:p>","DOI":"10.1007\/s43441-026-00994-0","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:11:45Z","timestamp":1786367505000},"page":"1848-1860","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["BE-BOIN: A Dose Optimization Design Accommodating Backfill and Late-Onset Toxicity"],"prefix":"10.1007","volume":"60","author":[{"given":"Kai","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"994_CR1","unstructured":"US Food and Drug Administration guidance. Optimizing the dosage of human prescription drugs and biological products for the treatment of oncologic diseases guidance for industry . 2024."},{"issue":"3","key":"994_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/17407745231207085","volume":"21","author":"Y Yuan","year":"2024","unstructured":"Yuan Y, Zhou H, Liu S. Statistical and practical considerations in planning and conduct of dose-optimization trials. Clin Trials. 2024;21(3):273\u201386.","journal-title":"Clin Trials"},{"issue":"2","key":"994_CR3","first-page":"27","volume":"30","author":"B Huang","year":"2023","unstructured":"Huang B, Yuan Y. Design strategies for dose optimization in oncology drug development. American Statistical Association Biopharmaceutical Report. 2023;30(2):27\u201332.","journal-title":"American Statistical Association Biopharmaceutical Report"},{"key":"994_CR4","doi-asserted-by":"crossref","unstructured":"Jiang L, Yuan Y. Seamless phase II\/III design: a useful strategy to reduce the sample size for dose optimization. J Natl Cancer Inst. 2023, 115(9):1092\u20138.","DOI":"10.1093\/jnci\/djad103"},{"key":"994_CR5","doi-asserted-by":"publisher","first-page":"106605","DOI":"10.1016\/j.cct.2021.106605","volume":"111","author":"HM Dehbi","year":"2021","unstructured":"Dehbi HM, O\u2019Quigley J, Iasonos A. Controlled backfill in oncology dose-finding trials. Contemp Clin Trials. 2021;111:106605.","journal-title":"Contemp Clin Trials"},{"issue":"3","key":"994_CR6","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1177\/17407745231160092","volume":"20","author":"H Barnett","year":"2023","unstructured":"Barnett H, Boix O, Kontos D, Jaki T. Backfilling cohorts in phase I dose-escalation studies. Clin Trials. 2023;20(3):261\u20138.","journal-title":"Clin Trials"},{"issue":"1","key":"994_CR7","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12874-024-02398-w","volume":"24","author":"X Chen","year":"2024","unstructured":"Chen X, Zhang J, Li B, Yan F. Determining doses for backfill cohorts based on patient-reported outcome. BMC Med Res Methodol. 2024;24(1):270.","journal-title":"BMC Med Res Methodol"},{"key":"994_CR8","doi-asserted-by":"publisher","first-page":"107567","DOI":"10.1016\/j.cct.2024.107567","volume":"142","author":"L Pin","year":"2024","unstructured":"Pin L, Villar SS, Dehbi HM. Implementing and assessing Bayesian response-adaptive randomisation for backfilling in dose-finding trials. Contemp Clin Trials. 2024;142:107567.","journal-title":"Contemp Clin Trials"},{"issue":"4","key":"994_CR9","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1158\/1078-0432.CCR-23-2585","volume":"30","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Yuan Y, Korn EL, Freidlin B. Backfilling patients in phase I dose-escalation trials using bayesian optimal interval design (BOIN). Clin Cancer Res. 2024;30(4):673\u20139.","journal-title":"Clin Cancer Res"},{"key":"994_CR10","doi-asserted-by":"crossref","unstructured":"Zhao Y, Liu R, Lin J, Yuan Y. BARD: a seamless two-stage dose optimization design integrating backfill and adaptive. Clin Trials. 2025;22(4):393\u2013404.","DOI":"10.1177\/17407745251350596"},{"issue":"13","key":"994_CR11","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1200\/JCO.2010.31.9236","volume":"29","author":"S Postel-Vinay","year":"2011","unstructured":"Postel-Vinay S, Gomez-Roca C, Molife LR, et al. Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities? J Clin Oncol. 2011;29(13):1728\u201335.","journal-title":"J Clin Oncol"},{"issue":"18","key":"994_CR12","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","volume":"33","author":"JS Weber","year":"2015","unstructured":"Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. J Clin Oncol. 2015;33(18):2092\u20139.","journal-title":"J Clin Oncol"},{"key":"994_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2018.10.017","volume":"107","author":"Y Kanjanapan","year":"2019","unstructured":"Kanjanapan Y, Day D, Butler MO, et al. Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials. Eur J Cancer. 2019;107:1\u20137.","journal-title":"Eur J Cancer"},{"issue":"16","key":"994_CR14","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMp2109826","volume":"385","author":"M Shah","year":"2021","unstructured":"Shah M, Rahman A, Theoret MR, Pazdur R. The drug-dosing conundrum in oncology - when less is more. N Engl J Med. 2021;385(16):1445\u20137.","journal-title":"N Engl J Med"},{"issue":"30","key":"994_CR15","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1200\/JCO.22.00371","volume":"40","author":"J Fourie Zirkelbach","year":"2022","unstructured":"Fourie Zirkelbach J, Shah M, Vallejo J, et al. Improving dose-optimization processes used in oncology drug development to minimize toxicity and maximize benefit to patients. J Clin Oncol. 2022;40(30):3489\u2013500.","journal-title":"J Clin Oncol"},{"issue":"4","key":"994_CR16","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1111\/j.0006-341X.2000.01177.x","volume":"56","author":"YK Cheung","year":"2000","unstructured":"Cheung YK, Chappell R. Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics. 2000;56(4):1177\u201382.","journal-title":"Biometrics"},{"key":"994_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2307\/2531628","volume":"46","author":"J O\u2019Quigley","year":"1990","unstructured":"O\u2019Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics. 1990;46:33\u201348.","journal-title":"Biometrics"},{"issue":"4","key":"994_CR18","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1214\/13-AOAS661","volume":"7","author":"S Liu","year":"2013","unstructured":"Liu S, Yin G, Yuan Y. Bayesian data augmentation dose finding with continual reassesment method and delayed toxicity. Ann Appl Stat. 2013;7(4):1837\u20132457.","journal-title":"Ann Appl Stat"},{"issue":"495","key":"994_CR19","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1198\/jasa.2011.ap09476","volume":"106","author":"Y Yuan","year":"2011","unstructured":"Yuan Y, Yin G. Robust EM continual reassessment method in oncology dose finding. J Am Stat Assoc. 2011;106(495):818\u201331.","journal-title":"J Am Stat Assoc"},{"issue":"20","key":"994_CR20","doi-asserted-by":"publisher","first-page":"4921","DOI":"10.1158\/1078-0432.CCR-18-0246","volume":"24","author":"Y Yuan","year":"2018","unstructured":"Yuan Y, Lin R, Li D, Nie L, Warren KE. Time-to-event bayesian optimal interval design to accelerate phase I trials. Clin Cancer Res. 2018;24(20):4921\u201330.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"994_CR21","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/biostatistics\/kxz007","volume":"21","author":"R Lin","year":"2020","unstructured":"Lin R, Yuan Y. Time-to-event model-assisted designs for dose-finding trials with delayed toxicity. Biostatistics. 2020;21(4):807\u201324.","journal-title":"Biostatistics"},{"key":"994_CR22","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/rssc.12089","volume":"64","author":"S Liu","year":"2015","unstructured":"Liu S, Yuan Y. Bayesian optimal interval designs for phase I clinical trials. J R Stat Soc: Ser C: Appl Stat. 2015;64:507\u201323.","journal-title":"J R Stat Soc: Ser C: Appl Stat"},{"key":"994_CR23","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1158\/1078-0432.CCR-16-0592","volume":"22","author":"Y Yuan","year":"2016","unstructured":"Yuan Y, Hess KR, Hilsenbeck SG, Gilbert MR. Bayesian optimal interval design: a simple and well-performing design for phase I oncology trials. Clin Cancer Res. 2016;22:4291\u2013301.","journal-title":"Clin Cancer Res"},{"key":"994_CR24","doi-asserted-by":"publisher","DOI":"10.1201\/9780429052781","volume-title":"Model-assisted bayesian designs for dose finding and optimization: methods and applications","author":"Y Yuan","year":"2022","unstructured":"Yuan Y, Lin R, Lee JJ. Model-assisted bayesian designs for dose finding and optimization: methods and applications. Boca Raton, FL: Chapman and Hall\/CRC; 2022."},{"issue":"3","key":"994_CR25","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1177\/17407745231221152","volume":"21","author":"L Biard","year":"2024","unstructured":"Biard L, Andrillon A, Silva RB, Lee SM. Dose optimization for cancer treatments with considerations for late-onset toxicities. Clin Trials. 2024;21(3):322\u201330.","journal-title":"Clin Trials"},{"key":"994_CR26","doi-asserted-by":"publisher","unstructured":"Chen K, Chen T, Zhang Y, Lin R, Yuan Y. Practical considerations for using the TITE-BOIN design to handle late- onset toxicity or fast accrual in phase I trials. Clin Cancer Res https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-3669","DOI":"10.1158\/1078-0432.CCR-24-3669"},{"issue":"15","key":"994_CR27","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1002\/sim.10093","volume":"43","author":"P Yang","year":"2024","unstructured":"Yang P, Li D, Lin R, Huang B, Yuan Y. Design and sample size determination for multiple-dose randomized phase II trials for dose optimization. Stat Med. 2024;43(15):2972\u201386.","journal-title":"Stat Med"},{"issue":"28","key":"994_CR28","doi-asserted-by":"publisher","first-page":"5299","DOI":"10.1002\/sim.8361","volume":"38","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Lee JJ, Yuan Y. A utility-based bayesian optimal interval (U-BOIN) phase I\/II design to identify the optimal biological dose for targeted and immune therapies. Stat Med. 2019;38(28):5299\u2013316.","journal-title":"Stat Med"},{"key":"994_CR29","doi-asserted-by":"crossref","unstructured":"Lin R, Zhou Y, Yan F, Li D, Yuan Y. BOIN12: bayesian optimal interval phase I\/II trial design for utility-based dose finding in immunotherapy and targeted therapies. JCO Precis Oncol. 2020;4:PO.20.00257.","DOI":"10.1200\/PO.20.00257"},{"issue":"2","key":"994_CR30","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1080\/19466315.2024.2365630","volume":"17","author":"G D\u2019Angelo","year":"2024","unstructured":"D\u2019Angelo G, Gong M, Marshall J, Yuan Y, Li X. U-MET: utility-based dose optimization approach for multiple-dose randomized trial designs. Stat Biopharm Res. 2024;17(2):211\u201321.","journal-title":"Stat Biopharm Res"},{"key":"994_CR31","doi-asserted-by":"crossref","unstructured":"Wang S, Yuan Y, Liu S. Randomized optimal selection design for dose optimization. Biometrics. 2025;81(4).","DOI":"10.1093\/biomtc\/ujaf124"},{"key":"994_CR32","doi-asserted-by":"publisher","first-page":"e2470","DOI":"10.1002\/pst.2470","volume":"24","author":"K Takeda","year":"2025","unstructured":"Takeda K, Zhu J, Hirakawa A. BF-BOIN-ET: a backfill bayesian optimal interval design using efficacy and toxicity outcomes for dose optimization. Pharm Stat. 2025;24:e2470.","journal-title":"Pharm Stat"}],"container-title":["Therapeutic Innovation &amp; Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-00994-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-026-00994-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-00994-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:07:08Z","timestamp":1793369228000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-026-00994-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["994"],"URL":"https:\/\/doi.org\/10.1007\/s43441-026-00994-0","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}